Biosense Webster Introduces the THERMOCOOL(R) SF Irrigated Catheter in the European Union

State-of-the-Art Irrigated Ablation Catheter Offers a Unique Design and Industry Leading Cooling Efficiency

WATERLOO, Belgium, May 13, 2010 - Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment
of cardiac arrhythmias, announced today the completion of the first clinical
cases with the new THERMOCOOL(R) SF Irrigated Ablation catheter in the
European Union, following recent CE Mark approval. The THERMOCOOL(R) SF
catheter is the most advanced Biosense Webster irrigated ablation catheter
for use by electrophysiologists in treating cardiac arrhythmias, commonly
referred to as irregular heart rhythms.

The THERMOCOOL (R) SF Irrigated catheter is the next generation in
irrigated ablation catheters and builds upon the industry leading
THERMOCOOL(R) irrigated catheter platform. The THERMOCOOL (R) SF catheter's
unique design and porous tip technology provides EPs with uniform cooling
across the entire catheter tip and allows efficient cooling at half the flow
rate.

"The THERMOCOOL(R) SF Irrigated Catheter is the latest advancement in
irrigated ablation catheter design with its groundbreaking and unique porous
tip technology," said Shlomi Nachman, Worldwide President, Biosense Webster,
Inc. "This innovation further builds upon our clear leadership position in
the electrophysiology market and reinforces our long-standing commitment to
electrophysiologists and their patients. "We are extremely pleased this
exciting new product will be launched throughout the European Union over the
coming months."

Unlike competitive irrigated technologies which offer localized cooling,
the cutting edge catheter design and breakthrough porous tip technology of
the THERMOCOOL(R) SF catheter allow for uniform cooling of the entire
catheter tip when ablating. This in turn allows for efficient fluid delivery
within the catheter itself and allows heat to dissipate across the entire
catheter tip. As a result, cooling efficiency is increased and the flow rate
is reduced.

Prof. Gerd Hindricks of the Heart Center at the University of Leipzig
Hospital commented on his recent experience with Biosense Webster's new
catheter platform."The THERMOCOOL (R) SF catheter is a new and exciting
technology that represents a significant advancement in irrigated ablation
for electrophysiologists." "I have been extremely impressed with the features
& capabilities of the THERMOCOOL (R) SF catheter." "My first clinical
experience indicates that due to the strategic placement of the holes around
the entire surface area of the tip, cooling efficiency and lesion induction
may be improved to complete Atrial Fibrillation ablation procedures in a
safe, effective, and timely manner."

"Procedure time & safety concerns are consistently cited by EPs as the
most significant barrier to increased use of ablation therapy to treat
cardiac arrhythmias," added Nachman. "All of our products are being developed
with the aim of addressing these concerns."

The ThermoCool SF(R) catheter is the latest in a series of innovations
from Biosense Webster. In recent months, the company has launched its
ground-breaking new 3D mapping platform, the CARTO(TM) 3 System in Europe and
the NAVISTAR (R) & Celsius(R) RMT THERMOCOOL(R) Catheters globally.

The NAVISTAR(R) THERMOCOOL(R) Catheters, including its bidirectional EZ
STEER(R) Catheter platform, remains the first and only US Food & Drug
Administration approved catheter for the safe and effective treatment of drug
refractory recurrent symptomatic paroxysmal atrial fibrillation when used
with the CARTO(R) System.

About Biosense Webster, Inc.

Biosense Webster, Inc., a Johnson & Johnson company, pioneered
electrophysiology diagnostic catheters more than 30 years ago and continues
to lead the industry as an innovative provider of advanced diagnostic,
therapeutic and mapping tools. As the leader in navigation systems and
ablation therapy, Biosense Webster, Inc.'s technology includes the largest
installed base of navigation systems worldwide in leading hospitals and
teaching institutions. With its proprietary products the company is changing
the way electrophysiologists diagnose and treat arrhythmias.

    Contact: Name:
    Ulrike Domany,
    Director Public Affairs & Communication EMEA,
    (o) +43-1-36025-396,
    (m) +43-664-83-504-83.

Contact: Name: Ulrike Domany, Director Public Affairs & Communication EMEA, (o) +43-1-36025-396, (m) +43-664-83-504-83.